About Us

With an eye on patients™

we are committed to developing solutions to help people facing serious eye disorders. At EyePoint Pharmaceuticals, you can see our dedication in action.

Our Leadership

Nancy Lurker

President & Chief Executive Officer & Board Director

Nancy Lurker

President & Chief Executive Officer & Board Director

President, CEO and Board Director Nancy Lurker leads our mission to improve the lives of people facing serious eye disorders. With over 30 years in the pharmaceutical industry driving scientific and commercial innovation across public and private companies, she has a proven track record of maximizing the potential of new therapies and implementing US and global drug launches in diverse therapy areas.

Jay Duker, MD

Chief Operating Officer

Jay Duker, MD

Chief Operating Officer

Chief Operating Officer, Jay S. Duker, M.D. is a leading retinal disease expert with more than 30 years in the field of ophthalmology focused on improving eyesight and preventing blindness, holding roles in clinical, research, business, start-ups, and academic settings.

George O. Elston

Chief Financial Officer

George O. Elston

Chief Financial Officer

Mr Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly traded and privately held organizations.

Ron Honig

Chief Legal Officer & Company Secretary

Ron Honig

Chief Legal Officer & Company Secretary

Mr Honig brings more than 25 years of legal experience in the medical device, biotechnology, contract manufacturing, and legal services industries to his role at EyePoint, which he has held since November 2018.

Scott Jones

Chief Commercial Officer

Scott Jones

Chief Commercial Officer

With a background in developing commercial and growth strategy, Mr Jones brings significant experience commercializing drugs and devices globally.

Jennifer Leonard

Chief People Officer & SVP, IT

Jennifer Leonard

Chief People Officer & SVP, IT

Ms Leonard has over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management, and culture development experience.

Dario Paggiarino, MD

Senior Vice President & Chief Medical Officer

Dario Paggiarino, MD

Senior Vice President & Chief Medical Officer

Dr Paggiarino joined EyePoint from Lpath, where he served as Senior Vice President and Chief Development Officer. Dr Paggiarino earned his degree in medicine and general surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.

Said Saim, PhD

Chief Technology Officer

Said Saim, PhD

Chief Technology Officer

Dr Saim has more than 25 years of product development experience. Dr Saim has published 22 papers in engineering and science journals, holds 18 patents, and earned a PhD in chemical engineering from the University of Kansas.

Isabelle Lefebvre

Chief Regulatory Officer

Isabelle Lefebvre

Chief Regulatory Officer

Ms. Lefebvre brings over 30 years of regulatory affairs experience in pharmaceuticals, biologics, and medical devices across all phases of development. Ms. Lefebvre has strong Ophthalmic/Ocular experience having spent nearly a decade of her career at Bausch Health where she led the successful approvals of both LOTEMAX gel and VYZULTA^®.

Michael Pine

Chief Corporate Development & Strategy Officer

Michael Pine

Chief Corporate Development & Strategy Officer

Michael Pine brings strategic vision, analytics and an extensive deal sheet built over 20+ years in the pharmaceutical industry at both large and small organizations.

Board of Directors

Göran Ando, MD

Chairman of the Board

Wendy DiCicco

Director

Anthony P. Adamis

Director

David Guyer, MD

Director

John Landis, PhD, MS

Director

Ye (Victor) Liu

Director

Nancy Lurker

President & Chief Executive Officer

Scientific Advisory Board

Sophie J. Bakri

Sophie J. Bakri, MD, MBA, is Chair of the Department of Ophthalmology at Mayo Clinic, Rochester, MN and holds the Whitney and Betty MacMillan Professorship in Ophthalmology in Honor of Robert R. Waller, M.D.

Caroline R. Baumal

Caroline R. Baumal, MD, FASRS is a Professor of Ophthalmology at New England Eye Center, Tufts Medical Center in Boston, MA.

David S. Boyer

David S. Boyer, M.D. is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. He is Senior Partner at Retina-Vitreous Associates Medical Group.

Glenn J. Jaffe

Dr. Jaffe is the Robert Machemer Professor of Ophthalmology and a member of the vitreoretinal faculty at Duke University Eye Center. He is chief of the Retina Division, and founded and directs the Duke Reading Center.

Carl D. Regillo

Board Chair

Dr. Carl D. Regillo is Professor of Ophthalmology at Thomas Jefferson University, Chief of the Retina Service of Wills Eye Hospital and Founder of the Wills Eye Clinical Retina Research Unit in Philadelphia.

Rishi P. Singh

Dr. Rishi P. Singh, MD is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He also currently serves as the medical director of informatics at the Cleveland Clinic.

Charles Wykoff

Dr. Charles Wykoff is Managing Partner of the Retina Consultants of Texas Research Centers; Chairman of the Research and Clinical Trials Committee, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital.